Advances in targeted therapy for esophageal cancer
YM Yang, P Hong, WW Xu, QY He, B Li - Signal transduction and …, 2020 - nature.com
Esophageal cancer (EC) is one of the most lethal cancers in the world, and its morbidity and
mortality rates rank among the top ten in China. Currently, surgical resection, radiotherapy …
mortality rates rank among the top ten in China. Currently, surgical resection, radiotherapy …
A global view of hepatocellular carcinoma: trends, risk, prevention and management
Hepatocellular carcinoma (HCC) is the fourth most common cause of cancer-related death
worldwide. Risk factors for HCC include chronic hepatitis B and hepatitis C, alcohol …
worldwide. Risk factors for HCC include chronic hepatitis B and hepatitis C, alcohol …
[HTML][HTML] VEGF/VEGFR-targeted therapy and immunotherapy in non-small cell lung cancer: targeting the tumor microenvironment
Non-small cell lung cancer (NSCLC) is the leading cause of death by cancer worldwide.
Despite developments in therapeutic approaches for the past few decades, the 5-year …
Despite developments in therapeutic approaches for the past few decades, the 5-year …
Recent advances in systemic therapy for hepatocellular carcinoma
H Zhang, W Zhang, L Jiang, Y Chen - Biomarker Research, 2022 - Springer
Hepatocellular carcinoma (HCC) is one of the most common and lethal malignant tumors in
the world. Therapeutic options for advanced HCC are limited. Systemic treatment, especially …
the world. Therapeutic options for advanced HCC are limited. Systemic treatment, especially …
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind …
Background Patients with advanced hepatocellular carcinoma and increased α-fetoprotein
concentrations have poor prognosis. We aimed to establish the efficacy of ramucirumab in …
concentrations have poor prognosis. We aimed to establish the efficacy of ramucirumab in …
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled …
K Nakagawa, EB Garon, T Seto, M Nishio… - The Lancet …, 2019 - thelancet.com
Background Dual blockade of the EGFR and VEGF pathways in EGFR-mutated metastatic
non-small-cell lung cancer (NSCLC) is supported by preclinical and clinical data, yet the …
non-small-cell lung cancer (NSCLC) is supported by preclinical and clinical data, yet the …
PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
Q Li, J Han, Y Yang, Y Chen - Frontiers in Immunology, 2022 - frontiersin.org
Hepatocellular carcinoma (HCC) has a high prevalence and mortality rate worldwide.
Sorafenib monotherapy has been the standard of first-line treatment for advanced HCC for a …
Sorafenib monotherapy has been the standard of first-line treatment for advanced HCC for a …
EASL clinical practice guidelines: management of hepatocellular carcinoma
Liver cancer is the fifth most common cancer and the second most frequent cause of cancer-
related death globally. Hepatocellular carcinoma represents about 90% of primary liver …
related death globally. Hepatocellular carcinoma represents about 90% of primary liver …
Hepatocellular carcinoma immune landscape and the potential of immunotherapies
Hepatocellular carcinoma (HCC) is the most common liver tumor and among the deadliest
cancers worldwide. Advanced HCC overall survival is meager and has not improved over …
cancers worldwide. Advanced HCC overall survival is meager and has not improved over …
[HTML][HTML] Dual EGFR-VEGF pathway inhibition: a promising strategy for patients with EGFR-mutant NSCLC
The vascular endothelial growth factor (VEGF) pathway has been recognized as a key
mediator of angiogenesis to support tumorigenesis. Multiple therapeutic agents targeting …
mediator of angiogenesis to support tumorigenesis. Multiple therapeutic agents targeting …